RSS

Microbiotica

Cambridge Innovation Capital portfolio company, Microbiotica, has entered into a multi-year strategic collaboration to discover, develop and commercialise biomarkers, targets and medicines for inflammatory bowel disease (IBD) with Genentech. Read more

News